Pharmaceuticals

CStone Announces the NDA Approval of GAVRETO® (pralsetinib) for the Treatment of RET Fusion-Positive treatment-naïve (first-line) and pretreated Non-Small Cell Lung Cancer (NSCLC) in Hong Kong, China

* GAVRETO is the first highly selective rearranged during transfection (RET) inhibitor approved inHong Kong, China for the treatment of RET fusion-positive metastatic non-small cell lung cancer * GAVRETO is CStone's second therapy approved in Hong Kong, China * GAVRETO is CStone's ninth NDA ...

2022-07-15 08:02 3243

Oncoshot Receives Funding To Expand Cancer Data Sharing Capabilities For Hospitals and Industry

SINGAPORE, July 14, 2022 /PRNewswire/ -- Oncoshot today announced a pre-series A funding round led by MassMutual Ventures (MMV). Other investors for this stage come from a suite of healthtech veterans that include Milltrust International and health industry angel investors.  This funding wi...

2022-07-14 15:30 2361

GenScript ProBio and DAAN Bio Therapeutics, Sign a Strategic Cooperation MOU for the Discovery and Development of Novel Drugs

SEOUL, South Korea, July 14, 2022 /PRNewswire/ -- On the July 14, 2022, GenScript ProBio (Brian Ho-sung Min, CEO), a global CDMO, and DAAN Bio Therapeutics (Byoung Chul Cho, Co-Founder & CEO), an innovative new drug developer such as antibody treatments and cell therapy drugs, announced that the...

2022-07-14 13:00 2139

Triastek announces research collaboration with Lilly to explore the application of 3D printing technology in oral delivery of drugs

NANJING, China, July 14, 2022 /PRNewswire/ -- On July 13, 2022, Triastek, Inc. ("Triastek") announced a collaboration with Eli Lilly and Company ("Lilly"), a leading global pharmaceutical company, to leverage the advantages of 3D printing technology to enable precisely targeted and programmed rel...

2022-07-14 09:00 2578

U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted for Individuals Aged 18 and Over

* Novavax' vaccine is the first protein-based COVID-19 vaccine authorized in the U.S. * Immunizations with the Novavax COVID-19 Vaccine, Adjuvanted as a primary series will begin upon product release and once a policy recommendation from the CDC is received GAITHERSBURG, Md., July 14, 2022 /P...

2022-07-14 06:06 2510

Glenmark Pharmaceuticals and SaNOtize Announce Peer Reviewed Publication of Its Phase 3 Clinical Trials on SaNOtize's Novel Nitric Oxide Nasal Spray for COVID-19 in Lancet Journal

MUMBAI, India and VANCOUVER, BC, July 13, 2022 /PRNewswire/ -- Glenmark Pharmaceuticals Limited (Glenmark), an innovation-driven, global pharmaceutical company and SaNOtize Research and Development Corp, today announced thatThe Lancet Regional Health Southeast Asia (TLRHSEA) – peer reviewed, high...

2022-07-13 20:06 2620

Brii Biosciences Appoints Dr. Susannah Cantrell as Chief Business Officer

Strategic executive hire adds to Company's global leadership team and positions the Company for continued growth DURHAM, N.C.and BEIJING, July 13, 2022 /PRNewswire/ -- Brii Biosciences Limited  ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national...

2022-07-13 19:00 2280

EVERSANA™ Announces Strategic Partnership with Compai Pharma to Expand Commercialisation Services Across the Asia Pacific Region

CHICAGO and SINGAPORE, July 13, 2022 /PRNewswire/ -- EVERSANA™, a pioneer of next-generation commercial services to the global life sciences industry with its Asian regional headquarters inSingapore and offices across Japan, China and other countries in the area, and Compai Pharma, an enterprisin...

2022-07-13 08:57 1813

Amaran Biotech Introduces the First Fully-Automated Robotic Aseptic Filling Line in Taiwan During Bio Asia-Taiwan 2022 7/28-7/31

HSINCHU, July 13, 2022 /PRNewswire/ -- Amaran Biotechnology Inc., a subsidiary ofTaiwan's OBI Pharma Inc., today announced that the construction of its fully-automated aseptic filling line and facilities, a first inTaiwan, has been completed. The new facility minimizes the risks of human factors ...

2022-07-13 08:00 3504

U.S. Government Secures 3.2 Million Doses of Novavax COVID-19 Vaccine

* Agreement will provide the first protein-based vaccine option in the U.S., pending FDA Emergency Use Authorization and CDC recommendation GAITHERSBURG, Md. ,July 11, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-gene...

2022-07-11 20:10 2903

SCG Cell Therapy Announces U.S FDA Clearance of Investigational New Drug Application for SCG101, SCG's Novel TCR-T Cell Therapy For Hepatitis B-related Liver Cancers

SINGAPORE, July 11, 2022 /PRNewswire/ -- Singapore-based SCG Cell Therapy Pte Ltd ("SCG") announced that U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for SCG101, an investigational T-cell receptor (TCR) T cell therapy for patients with hepati...

2022-07-11 13:34 2316

Kevin Richardson appointed as CEO, Telix Americas

MELBOURNE and INDIANAPOLIS, July 11, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to announce thatKevin Richardson, a senior global executive with a career focus on sales, marketing and business operations in the oncology and radiopharmaceutical mar...

2022-07-11 08:13 2325

HaemaLogiX strengthens Board with appointment of Dr. Geoff Nichol

* Dr. Geoff Nichol, M.B., Ch.B., M.B.A., joins HaemaLogiX's Board of Directors as Non-Executive Director, bringing nearly 30 years of global drug development experience * Past achievements include approval of Augmentin BID for adults and children, plus foundational clinical development of bre...

2022-07-08 05:30 2486

Insilico Medicine identified multiple new targets for amyotrophic lateral sclerosis (ALS) using its AI-driven target discovery engine

* Insilico and its collaborators scoured massive datasets and found genes relevant to ALS through PandaOmics™, Insilico's proprietary AI-driven target identification engine. * 28 targets were identified from CNS and diMN samples; for 18 targets (64%), suppression moderately or strongly rescue...

2022-07-08 04:00 2734

Brii Biosciences Announces Commercial Launch of its Amubarvimab/Romlusevimab Combination Therapy for COVID-19 in China

The Company is working closely with its commercial partners to supply the combination therapy to patients in need  Brii Bio progressed the combination therapy from discovery to global Phase 3 data readout  and first regulatory approval by the China NMPA in less than 20 months, validating the Com...

2022-07-07 07:10 3405

Guardant Health and Adicon announce strategic partnership to offer comprehensive genomic profiling tests to accelerate development of new cancer therapies in China

Collaboration will provide biopharmaceutical companies access to Guardant Health's broad portfolio of cancer tests to help advance drug development programs and their clinical trials SINGAPORE, July 6, 2022 /PRNewswire/ -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company,...

2022-07-06 18:17 3060

Ascletis Announces U.S. IND Filing of Oral RdRp Inhibitor Drug Candidate ASC10 for COVID-19

-- ASC10 is an oral small molecule drug candidate, which is in-house discovered and developed, and Ascletis retains full global rights for its development and commercialization --This IND filing of ASC10 in the U.S. will accelerate Ascletis' global multi-center clinical studies on ASC10 and bett...

2022-07-06 08:10 3365

Novavax Nuvaxovid™ COVID-19 Vaccine Conditionally Authorized in the European Union for Adolescents Aged 12 Through 17

* Nuvaxovid™ COVID-19 vaccine is the first protein-based option for adolescents aged 12 through 17 inEurope GAITHERSBURG, Md., July 5, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious inf...

2022-07-05 23:37 2798

Endurance RP Limited (SEHK:0575.HK) Operational Update on the PE Prevention Drug Fortacin™ / Senstend™

Phase 3 Study in China is Estimated to Complete in November 2022 HONG KONG, July 5, 2022 /PRNewswire/ -- Endurance RP Limited ("Endurance Longevity" or the "Company" and together with its subsidiaries, the "Group"; stock code: 0575.HK) is pleased to provide updates on the PE prevention drug - Fo...

2022-07-05 12:06 2569

JW Therapeutics Announces Initiation of Clinical Study of JWATM204 in Patients with Advanced Hepatocellular Carcinoma

SHANGHAI, July 4, 2022 /PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced the initiation of phase I clinical study of JWATM204 in patients with advanced ...

2022-07-04 19:30 3507
1 ... 69707172737475 ... 181